Guardian Pharmacy Services, Inc. (NYSE: GRDN) announced a restructuring of its executive leadership team effective July 1, 2026. The changes involve the retirement of a long-standing executive and the appointment of new officers to oversee operations and finance. The company emphasized that these moves reflect a disciplined succession strategy.

Kendall Forbes, Executive Vice President of Sales & Operations, will retire effective July 1, 2026. Forbes has served in this role since 2004. Fred Burke, President and Chief Executive Officer, credited Forbes with building the company's sales and operations infrastructure over a 22-year tenure.

David Morris, currently Executive Vice President and Chief Financial Officer, will assume the role of Chief Operating Officer upon Forbes' retirement. Morris has served as CFO since the company's founding. Burke stated that Morris's deep understanding of the business and financial discipline make him suited to lead operating functions.

Succeeding Morris as Chief Financial Officer is Will Mudd. Mudd currently serves as Senior Vice President, Finance, a position he has held since 2012. His oversight has included financial accounting, reporting, revenue cycle management, and human resources. Prior to joining Guardian, Mudd spent approximately ten years in the audit services group at Grant Thornton.

Leadership Transition Details

The following table outlines the changes in Guardian Pharmacy Services' executive structure:

Burke highlighted the internal promotion of Mudd as a critical step for the company's finance team. Mudd played a key role in the company's transition to a public entity. The company operates a network of 61 licensed pharmacies serving approximately 207,000 residents as of March 31, 2026.

Truist Securities analyst David Macdonald has maintained a Buy rating on Guardian Pharmacy Service, raising the price target to $47 from the previous $43. The revised target indicates a positive outlook on the company's stock performance.

Analyst Recommendation

The decision to uphold the Buy rating comes alongside a higher price objective, suggesting potential upside for Guardian Pharmacy Service shares. The new target of $47 represents an increase over the prior estimate of $43.